Eye care company settles with J&J Surgical Vision for $199m

J&J had accused defendant of infringing patents related to cataract surgery | Company also complained its copyright-protected computer programs had been ripped off, alleging “piracy of a nearly unfathomable scale”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

J&J settles Amgen clash over blockbuster psoriasis drug

25 May 2023 Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

Big Pharma

J&J hit with suit over Neutrogena products

20 April 2023 Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.

Americas

J&J unit accuses rival of ‘shocking’ trade secrets theft

11 February 2021 A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.

More on this story

Big Pharma

J&J settles Amgen clash over blockbuster psoriasis drug

25 May 2023 Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

Big Pharma

J&J hit with suit over Neutrogena products

20 April 2023 Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.

Americas

J&J unit accuses rival of ‘shocking’ trade secrets theft

More on this story

Big Pharma

J&J settles Amgen clash over blockbuster psoriasis drug

25 May 2023 Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

Big Pharma

J&J hit with suit over Neutrogena products

20 April 2023 Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.

Americas

J&J unit accuses rival of ‘shocking’ trade secrets theft